HPLC-free peptide purification using novel capping and capture reagents
Capping and capture reagents in SPPS efficiently block unreacted amino groups and separate defective sequences, reducing purification time and solvent use, addressing the inefficiencies of traditional methods and achieving high-purity full-length peptides.
Patent Information
- Application Number
- JP2021539416
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-07
- Filing Date
- 2020-01-03
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-01-03
AI Technical Summary
Existing solid phase peptide synthesis (SPPS) methods face challenges in efficiently purifying full-length peptides due to the co-elution of truncated sequences with the desired product, requiring large amounts of excess capping reagents and complex purification processes like preparative HPLC, which are costly and time-consuming.
The use of capping and capture reagents comprising a capping moiety, such as a carboxylic acid or activated carboxylic acid, and a capture moiety, such as a protected carbonyl group, to block unreacted amino groups and facilitate the separation of defective peptide sequences during SPPS, allowing for parallel purification without the need for harsh cutting steps.
This approach significantly reduces purification time and solvent use by up to 200-fold compared to conventional HPLC, effectively separates full-length peptides from truncated sequences, and eliminates residual moieties, achieving high purity without labor-intensive HPLC steps.
Smart Images

Figure 0007581210000011 
Figure 0007581210000012 
Figure 0007581210000013
Abstract
Description
[Technical field]
[0001] The present invention relates to the use of capping and capture reagents in solid phase peptide synthesis. The present invention further relates to a method of solid phase peptide synthesis, in which a capping and capture reagent according to the present invention is used. The present invention further relates to a method for solid phase peptide synthesis, in which a capping and capture reagent according to the present invention is used to facilitate subsequent purification of the (full-length) synthetic peptide during peptide synthesis. The present invention also relates to a kit comprising a capping and capture reagent according to the present invention and an aminooxy resin or a hydrazine resin, and the use of said kit. [Background technology]
[0002] Solid phase peptide synthesis (SPPS) is the main method for the synthesis of short to medium length peptides (Merrifield, RB, Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society, 1963, vol. 85(14), pp. 2149-2154). In particular, Fmoc-based strategies have become the predominant methodology used (WC Chan PD White Eds., Fmoc Solid Phase Peptide Synthesis, A Practical Approach. Oxford University Press: 2000). Even with high coupling efficiency, small amounts of unreacted amino groups accumulate during the stepwise synthesis. To avoid uncontrolled accumulation of deletion sequences with one or more residues missing at different positions, a large excess of capping reagent is added to the resin after each coupling step to ensure that all remaining free amines are completely quenched. Acetic anhydride is usually used for this purpose. The most tedious and time-consuming aspect of SPPS remains the purification of the crude peptide by preparative HPLC. Despite capping strategies, some truncated sequences co-elute with the full-length product and can be difficult to separate.To facilitate resolution of the purification problem, various reagents have been developed to tag incomplete sequences and modify their HPLC elution profile or their solubility (Shogren-Knaak, MA; McDonnell, KA; Imperiali, B., α-Chloroacetyl capping of peptides: an N-terminal capping strategy suitable for Edman sequencing. Tetrahedron Letters, 2000, 41(6), 827-829; Canne, LE; Winston, RL; Ken, SBH, Synthesis of a versatile purification handle for use with Boc chemistry solid phase peptide synthesis. Tetrahedron Letters, 1997, 38(19), 3361-3364; Montanari, V.; Kumar, K., Just Add Water: A New Fluorous Capping Reagent for Facile Purification of Peptides Synthesized on the Solid Phase. Journal of the American Chemical Society, 1999, 10, 1111-1115). Society, 2004, 126(31), 9528-9529; Montanari, V.; Kumar, K., A Fluorous Capping Strategy for Fmoc-Based Automated and Manual Solid-Phase Peptide Synthesis. European Journal of Organic Chemistry, 2006, 2006(4), 874-877).Instead, in a final step, the full-length peptide is modified with a moiety that allows the selective isolation of the desired product (Villain, M.; Vizzavona, J.; Rose, K., Covalent capture: a new tool for the purification of synthetic and recombinant polypeptides. Chemistry & Biology, 2001, 8(7), 673-679; Toshiaki, H.; Akira, T.; Ken'ichiroh, N.; Takeshi, S.; Toru, K.; Saburo, A., Peptide purification by affinity chromatography based on α-ketoacyl group chemistry. Journal of Peptide Science, 2009, 15(5), 369-376; Toshiaki, H.; Akira, T.; Toru, K.; Saburo, A.; Michio, M., Peptide purification using the chemoselective reaction between N-(methoxy)glycine and isothiocyanato‐functionalized resin. Journal of Peptide Science, 2016, 22(6), 379-382; Loibl, S. F.; Harpaz, Z.; Zitterbart, R.; Seitz, O., Total chemical synthesis of proteins without HPLC purification. Chemical Science, 2016, 7(11), 6753-6759).
[0003] For each coupling step, a large excess of coupling reagent must be added to the resin to ensure efficient capping, so expensive or complex synthetic reagents are not useful for routine applications. Terminal modification of full-length peptides while avoiding high costs poses another problem: the final product after purification still contains the purification handle or parts thereof, or, for example, if the biological activity of the peptide is in question, the use of a traceless cleavable linker is required. Several traceless linkers have been described in the literature, but the cleavage conditions must be carefully controlled so as not to contaminate the final product solution and to be harmless to the peptide.
[0004] Reagents that facilitate the purification of compounds synthesised on solid supports are disclosed, for example, in WO03 / 017930A2.
[0005] A fluorous capping reagent for easy purification of peptides synthesized on the solid phase is disclosed, for example, in Montanari, V.; Kumar, K., Just add water: a new fluorous capping reagent for facile purification of peptides synthesized on the solid phase. Journal of American Chemical Society, 2004, Vol. 126, pp. 9528-9529.
[0006] Nitrogen-containing heterocyclic compounds containing activated carboxylic acids and protected carbonyl groups are disclosed, for example, in WO2010 / 032437A1.
[0007] The inventors have been able to show that capping and scavenging reagents can be prepared starting from relatively cheap starting materials. For efficient capping in solid-phase peptide synthesis, often large excesses of capping reagents must be added every synthesis cycle. Only cheap, easily available reagents are practical for routine use. Summary of the Invention
[0008] The use of the capping and capture reagents of the present invention in solid-phase peptide synthesis provides significant time savings compared to preparative HPLC purification due to the possibility of parallelization of purification. In addition, solvent is saved up to about 200 times compared to conventional preparative HPLC. Terminal sequences that co-elute with the desired product on HPLC can be easily separated. The use of the capping and capture reagents of the present invention provides no residual moieties on the desired product compared to linker strategies using full-length peptide capture. Thus, no final cleavage step is required to obtain the final product (i.e., no contamination by by-products caused by cleavage or harsh cleavage conditions).
[0009] Thus, in a first aspect, the present invention relates to the use of a capping and capturing (cap-capt) reagent comprising a capping moiety and a capturing moiety in solid phase peptide synthesis, wherein the capping moiety is a carboxylic acid or an activated carboxylic acid and the capturing moiety is a protected carbonyl group.
[0010] According to the present invention, the cap-capt reagent is used in solid phase peptide synthesis (SPPS). Solid phase peptide synthesis allows the synthesis of peptide chains by sequential reactions of amino acid derivatives on a solid support with rapid synthesis. The solid support may consist of small polymeric resin beads functionalized with reactive groups (e.g., amine or hydroxyl groups) that are linked to the emerging peptide chain. Each amino acid that will be coupled to the N-terminus of the peptide chain must be protected on its N-terminus and on the side chain if it contains a reactive functional group such as a carboxy, hydroxyl or amino group. Such protection can be achieved using appropriate protecting groups for the N-terminal amino group, such as Boc (acid labile) or Fmoc (fluorenylmethyloxycarbonyl) (base labile), and orthogonal protecting groups for the side chains, such as tert-butyl, benzyl, tert-butyloxycarbonyl (Boc), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), trityl, monomethoxytrityl (Mtr), benzyloxycarbonyl (Z), 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde), depending on the side chain and protection strategy used. The general SPPS procedure is a repeated cycle of alternating N-terminal deprotection and coupling reactions. The resin can be washed between each step. First, a protected amino acid is coupled to the resin using a coupling or activating reagent such as DIC / Oxyma or HBTU, and a base such as DIPEA. A capping step may be applied afterwards to block the unreacted amino group from further reaction in the next coupling step, using a capping reagent such as acetic anhydride. The amine is subsequently deprotected and then coupled with the free acid of the next amino acid. This cycle is repeated until the desired sequence is synthesized. At the end of the synthesis, the crude peptide is cleaved from the solid support, while simultaneously removing all protecting groups using a reagent strong acid or nucleophile such as trifluoroacetic acid (TFA). A scavenger such as water, thiol, sulfide or silane may be added to the TFA.The crude peptide can be precipitated from a non-polar solvent such as diethyl ether to remove soluble organic by-products.
[0011] During SPPS, full-length synthetic peptides of desired sequences / compositions can be obtained. However, despite the high efficiency of each coupling step, a small amount of amino acids on the growing peptide chain may not react with consecutive amino acids, resulting in truncated or defective peptide sequences. The defective peptide sequences represent the main by-products formed in SPPS. Compared to the main (full-length) synthetic peptide, the fraction of defective peptide sequences increases as the length and complexity of the selected peptide increases. The defective peptides may also be difficult or impossible to separate from the desired full-length synthetic peptide. The capping step described herein, i.e., the capping and capture reagent-based capping step described in this disclosure, blocks the terminal amino group of the defective peptide sequence, thus preventing it from reacting in further coupling steps and forming peptide sequences with amino acid deletions. Thus, this cap-capt reagent also provides a means for the purification of full-length synthetic peptides.
[0012] A "bad peptide" or "bad peptide sequence" according to the present disclosure is a peptide that has an unprotected amino group on the penultimate amino acid after the completion of the SPPS cycle. Those skilled in the art will appreciate that such truncated peptides are the result of incomplete coupling reactions. To prevent further coupling of the bad peptide in subsequent coupling steps, the bad peptide can be capped, which is routinely done with acetic anhydride. Alternatively, the bad peptide can be activated and reacted in the next synthesis cycle, thus resulting in an "n-1"-peptide, i.e., a peptide that closely resembles the full-length synthetic peptide, but is one amino acid shorter.
[0013] The capping and capture (cap-capt) reagent disclosed herein allows for capping of bad peptide sequences during peptide synthesis and removal of bad peptide sequences after solid-phase peptide synthesis. The capping moiety reacts with the first reactive group located on the by-product of SPPS, e.g., bad peptides, to prevent the bad peptide sequences from further reaction. The capture moiety, which is part of the capping and capture reagent, allows for the removal of those bad peptide sequences by chemoselectively reacting the capture moiety with additional reactive groups. Since the capture moiety is not present on the full-length synthetic peptide, but only on the capped bad peptide sequences, any bad peptides can be easily separated from the desired full-length synthetic peptide.
[0014] A reactive group is a chemical group capable of forming a bond, preferably a covalent bond with another reactive group.
[0015] In the present invention, the first reactive group is an amino group, specifically the terminal amino group on the defective peptide, which reacts with the capping moiety of the cap-capt reagent disclosed herein.
[0016] The further or second reactive group is a reactive group that reacts with the capture moiety of the cap-capt reagent. The second reactive group is located on the solid support.
[0017] Suitable second reactive groups are aminooxy or hydrazine groups.
[0018] According to the uses, methods and kits disclosed in the present invention, the cap-capt reagent comprises a capping moiety and a capture moiety, the capping moiety being a carboxylic acid or an activated carboxylic acid.
[0019] According to the present invention, the capture moiety is a protected carbonyl group. In one embodiment, the protected carbonyl group is an acetal or ketal.
[0020] Carboxylic acids are organic compounds that contain the carboxyl group -C(O)OH.
[0021] In one embodiment of the present invention, the capping moiety of the cap-capt reagent is a carboxylic acid group.
[0022] Activation of the cap-capt reagent in its carboxylic acid form can be carried out by treatment with a coupling reagent. Activation can be carried out before the cap-capt reagent is added to the mismatched peptide sequence. Alternatively, activation of the cap-capt reagent can be carried out while already in contact with the mismatched peptide sequence. In the latter case, activation can be carried out with at least one reagent that is also used for the solid phase peptide synthesis. For example, if a coupling reagent is used for activation of the cap-capt reagent, the coupling reagent can be the same as the coupling reagent used to couple the protected amino acids to build up the peptide sequence.
[0023] In one embodiment, the capping moiety is an activated carboxylic acid. Those skilled in the art are familiar with the term activated carboxylic acid. An activated carboxylic acid is a carboxylic acid derivative that is highly susceptible to nucleophilic attack. In one embodiment, an activated carboxylic acid is a carboxylic acid derivative that is reactive with an amino group. In one example, an amino group on a defective peptide reacts with an activated carboxylic acid to form an amide bond (or peptide bond).
[0024] Examples of activated carboxylic acids include acyl halides, anhydrides, pentafluorophenyl esters, N-hydroxysuccinimide esters or N-hydroxybenzotriazole esters.
[0025] In one embodiment of the invention, the cap-capture reagent comprises one capping moiety and one capture moiety.
[0026] In a further embodiment, the cap-capt reagent has the formula (I): [ka] [In the formula, R1 is hydrogen or optionally substituted alkyl; R2 is OR5 or a halogen; each R and R independently is optionally substituted alkyl or, together with the oxygen atom to which they are attached, forms an optionally substituted 5- or 6-membered ring; R5 is H, succinimide, pentafluorophenyl, benzotriazole, anhydride and [ka] is selected from and n is independently 0, 1, 2, 3 or 4.
[0027] "Alkyl" as used herein preferably refers to an alkyl group of the general formula C having 1 to 5 carbon atoms. n H 2n+1 "Optionally substituted alkyl" refers to a saturated branched or straight chain chemical group of the general formula C n H 2n+1 is a saturated branched or straight chain chemical group in which at least one of the hydrogen atoms has been replaced by a different group or atom, i.e., a substituent. Examples of substituents are halogens, -CN, -NO 2 , -C(O)N(R11) 2 , -COO(R11), -O(R11), -N(R11) 2 and R11 is independently H or C 1 ~C 3 It is an alkyl.
[0028] Optional substituents on the 5- or 6-membered ring which may be formed by each R3 and R4 together with the oxygen atom to which they are attached are, for example, alkyl, such as methyl or ethyl.
[0029] In one embodiment, the activated carboxylic acid comprises an ester bond formed with a derivative of a suitable coupling reagent known in the art. Certain embodiments of residues R2 or OR5, respectively, comprise a carboxylic acid and a carbodiimide, such as DCC (N,N'-dicyclohexylcarbodiimide), DIC (diisopropylcarbodiimide), EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), EDAC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) or WSC (water-soluble carbodiimide), optionally with an additive, such as HOBt (hydroxybenzotriazole), HOAt (1-hydroxy-7-azabenzotriazole), HOOBt, (3-hydroxy-1,2,3-benzotriazin-4-one), HOSu, (N-hydroxysuccinimide), Oxym In combination with aPure (2-cyano-2-(hydroxyimino)acetate) or DMAP (4-dimethylaminopyridine), phosphonium reagents such as BOP (benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate), PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), PyBrOP, (3-hydroxy-1,2,3-benzotriazin-4-one), PyAOP ((7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate), PyOxim ([ethylcyano(hydroxyimino)acetato-O 2]tri-1-pyrrolidinylphosphonium hexafluorophosphate) or DEPBT (3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one), in combination with aminium / uranium-immonium reagents such as TBTU, HBTU ((2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), HCTU (O-(1H-6-chlorobenzotriazol-1-yl)-1,1, 3,3-Tetramethyluronium hexafluorophosphate), HDMC (N-[(5-chloro-3-oxido-1H-benzotriazol-1-yl)-4-morpholinylmethylene]-N-methylmethanaminium hexafluorophosphate), TATU (O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate), HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5 -b]pyridinium 3-oxide hexafluorophosphate), COMU ((1-cyano-2-ethoxy-2-oxoethylideneaminooxy) dimethylamino-morpholino-carbenium hexafluorophosphate), TOTT (2-(1-oxy-pyridin-2-yl)-1,1,3,3-tetramethylisothiouronium tetrafluoroborate) or TFFH (tetramethylfluoroformamidinium hexafluorophosphate), or in combination with other It is formed by reacting in combination with a coupling reagent such as EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline), T3P (phosphonic acid propyl anhydride), DMTMM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride), BTC (benzene-1,3,5-tricarboxylic acid) or CDI (1,1'-carbonyldiimidazole) (see, for example, Aldrich, ChemFiles, 2007, Vol. 7, No. 2, Peptide Synthesis).
[0030] In a further embodiment, the capping and capture reagent comprises: [ka] [In the formula, R6, R7, R8 and R9 are each independently selected from hydrogen and alkyl; R10 is optionally substituted alkyl.
[0031] In one embodiment, each of R, R, R, and R is independently selected from hydrogen and C 1 ~C 3 is selected from alkyl.
[0032] Each of R6, R7, R8 and R9 may be hydrogen.
[0033] R10 may be methyl or ethyl.
[0034] R1 may independently be hydrogen, methyl or ethyl.
[0035] Residues R2 that are part of the capping moiety are independently selected from F, Cl and Br, O-succinimide, O-pentafluorophenyl, O-benzotriazole, anhydride and [ka] may be selected from the group consisting of:
[0036] cap-capt reagent is [ka] may be selected from:
[0037] In a preferred embodiment, the cap-capt reagent comprises: [ka] It is.
[0038] A further aspect of the present invention relates to a method for solid phase peptide synthesis (SPPS), in which the individual amino acids are coupled to one another via Fmoc-chemistry, and, after at least one coupling step, a capping and capture reagent according to the present invention is used for capping of mismatched peptide sequences.
[0039] Fmoc stands for 9-fluorenylmethyloxycarbonyl, a protecting group in organic chemical synthesis.
[0040] In Fmoc chemistry, which stands for solid-phase peptide synthesis, a peptide chain is assembled stepwise, one amino acid at a time, while attached to an insoluble (resin) support. Amino acids are protected at their amino termini with Fmoc groups and, after activation of their carboxylic acid termini, are coupled to the growing chain. The activated carboxylic acid of this amino acid reacts with the terminal amino group of the growing peptide chain. The Fmoc group is then removed by treatment with base, and the process is repeated. After the peptide is assembled, it is removed from the insoluble resin support, for example, by treatment with trifluoroacetic acid (TFA). Simultaneously, the protecting groups on the amino acid side chains are also removed to produce the crude linear peptide.
[0041] More specifically, a routine process for peptide synthesis using stepwise solid-phase Fmoc-chemistry includes: (a) swelling a resin compatible with peptide synthesis in a dipolar aprotic solvent; (b) deprotecting the Fmoc groups on the resin, if present, using a solution of piperidine in the dipolar aprotic solvent; (c) washing the resin after Fmoc deprotection with the dipolar aprotic solvent; (d) adding an Fmoc-amino acid, coupling reagent(s) (e.g., 2-(6-chloro-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) or 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) / 1-hydroxybenzotriazole (HOBt) and DIPE in a dipolar aprotic solvent for coupling to the deprotected resin. (e) charging the activated Fmoc-amino acid solution to the resin in a reactor; (f) coupling the activated Fmoc-amino acid to the N-terminal amino group on the resin; (g) washing the resin after coupling of each Fmoc-amino acid; (h) optionally capping unreacted amino groups, e.g., capping failed peptide sequences on the resin with a capping reagent (e.g., acetic anhydride); (i) repeating steps (b)-(h) until the full-length synthetic peptide is formed; (j) cleaving the desired peptide from the resin using a cleavage cocktail while simultaneously deprotecting the amino acid side chains; (j) filtering the cleavage mixture from the resin; and (k) evaporating and / or precipitating the filtrate and partially purifying the crude product from the concentrated solution using an organic solvent to produce a partially purified peptide.
[0042] As shown in the general outline of standard Fmoc synthesis above (see step (h)), a capping step using acetic anhydride can be used to cap unreacted amino groups, especially the amino group on the penultimate unreacted amino acid of the desired peptide sequence. However, when acetic anhydride is used, separation of full-length peptides from truncated peptides can be difficult and sophisticated HPLC methods are usually required.
[0043] According to the use and procedure disclosed herein, in step (h), the failure peptide is capped with the capping and capture reagent according to the present disclosure as outlined above. During said capping, an amide bond is formed between the capping moiety and the unprotected amino group (on the failure peptide sequence). Thus, at least one "failure peptide sequence" is obtained, which comprises a protected capture moiety and a full-length synthetic peptide, each of which reacts with the capping moiety of the cap-capt reagent and is bound to a solid phase. In the SPPS method according to the present invention, the failure peptide sequence comprises the cap-capt reagent bound via the capping step.
[0044] In a further aspect, the present invention relates to a method for the purification of a (full-length) synthetic peptide, comprising the steps of: - carrying out a solid phase peptide synthesis according to the invention, - cleaving the compound thus synthesized from the solid phase, - deprotecting the capture moiety, and - binding the deprotected capture moiety to a solid resin support, thereby binding at least one failure peptide sequence to the solid resin support; and - separating the full-length synthetic peptide from the solid resin support containing the defective peptides. The present invention relates to a method comprising the steps of:
[0045] In a preferred embodiment, the solid resin support is an aminooxy resin, or a hydrazine resin.
[0046] The individual steps of the method for purification of (full-length) synthetic peptides are exemplified below.
[0047] After completion of peptide synthesis, the synthesized peptide chain is cleaved from the solid phase. This cleavage step is carried out by adding a suitable reagent. Usually, a strong acid such as TFA (trifluoroacetic acid), TFA combined with a scavenger (nucleophile), for example, a mixture of TFA with an additive such as water, a silane such as TES (triethylsilane) or TIS (triisopropylsilane), a thiol such as mercaptoethanol, dithioerythritol (DTE), ethanedithiol (EDT) or dioxa-1,8-octane-dithiol (DODT), a sulfide such as thioanisole or ethyl methyl sulfide or an ether such as anisole, etc. are used.
[0048] Although it may be possible to cleave the synthesized full-length synthetic peptide from the solid phase without deprotecting the protected capture moiety in the failure peptide, conditions are usually selected that accomplish both cleavage of the synthetic peptide from the solid support and deprotection of the capture moiety. Thus, the capture moiety of the cap-capt reagent that is bound to the failure peptide (and any capture moiety of the cap-capt reagent that is still present) is deprotected. In a preferred embodiment, the deprotection step of the capture moiety is performed simultaneously with the cleavage step of cleaving the peptide from the resin to deprotect the side chain amino acid protecting groups, thus using the same reagents.
[0049] In one embodiment, the solid phase is filtered from the mixture. In this embodiment, the filtrate preferably comprises a mixture of full-length synthetic peptides and failure peptides that include the cap-capt reagent bound to the failure peptides.
[0050] In one embodiment, the deprotected capture moiety of the cap-capt reagent bound to the bad peptide is bound to a resin containing an amino group. In a preferred embodiment, the deprotected capture moiety is bound to an aminooxy resin or a hydrazine resin. The binding is achieved by adding the respective aminooxy resin or hydrazine resin to the deprotected capture moiety. Using the binding step, the bad peptide sequence (capped via the cap-capt reagent) is bound to the aminooxy resin or hydrazine resin. The binding between the deprotected capture group and the aminooxy resin or hydrazine resin is generally achieved via an oxime or hydrazone bond.
[0051] The aminooxy resin as well as the hydrazine resin comprises a solid support. Solid supports are generally known in the art and include beads, columns, arrays, multi-well plates, filters or other surface substrates. In one embodiment, the aminooxy resin or the hydrazine resin is in the form of beads, columns or filters, respectively. In one embodiment, the aminooxy resin or the hydrazine resin is in the form of beads or filters, respectively.
[0052] In a subsequent step, the full-length synthetic peptide is separated from the solid resin support, e.g., aminooxy or hydrazine resin, that has the abortive peptide sequence attached to it (via the cap-capt reagent). Separation can be accomplished, for example, by filtration, sedimentation, or centrifugation.
[0053] The separations described allow for efficient and cost-effective purification of synthesized synthetic peptides. Such purification does not require labor-intensive, expensive and time-consuming HPLC steps. Rather, several to many peptides synthesized according to the procedures disclosed herein can be purified economically and in parallel.
[0054] In a further aspect, the present invention is directed to a kit comprising the cap-capt reagent described herein and at least one aminooxy resin or hydrazine resin.
[0055] In a further aspect, the present invention is directed to the use of a kit comprising the cap-capt reagent described herein and at least one aminooxy resin or hydrazine resin for the separation of full-length peptides from error peptide sequences.
[0056] In a preferred embodiment, the kit is used for the purification of peptides obtained by solid phase peptide synthesis.
[0057] The use according to the present invention can be further defined as specified for the method of the present invention.In particular, with regard to the terms used in the further aspect of the present disclosure, they refer to the terms, examples and specific embodiments used in the first aspect of the present disclosure, but they are also applicable to the further aspect of the present disclosure.
[0058] In general, the disclosure is not limited to the specific methodologies, protocols, and reagents described herein, because these may vary. Moreover, the terms used herein are for the purpose of describing specific embodiments only, and are not intended to limit the scope of the disclosure. As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Similarly, the words "comprise," "contain," and "include" are interpreted as inclusive rather than exclusive.
[0059] Unless otherwise defined, all technical and scientific terms and any acronyms used herein have the same meaning as commonly understood by one of ordinary skill in the art of this disclosure. Although any methods and materials similar or equivalent to those described herein can be used in the practice presented herein, specific methods and materials are described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0060] The present disclosure is further illustrated by the following figures and examples, however, it is understood that unless specifically indicated otherwise, the figures and examples are included for illustrative purposes only and are not intended to limit the scope of the present disclosure. [Brief description of the drawings]
[0061] [Figure 1] The general reaction schemes for the synthesis of capping and scavenging reagents 1, or (1'), and 2, respectively, and amino-oxy PEGA resin 3 are illustrated. Ethyl 2,2-diethoxyacetate and ethyl-2-methyl-1,3-dioxolane-2-acetate (fractones) were selected as starting points for the synthesis of aldehydes and ketones containing capping moieties. The esters were hydrolyzed with NaOH (step a) and subsequently converted to the corresponding symmetrical anhydrides by treatment with dicyclohexylcarbodiimide (DCC) (step b). [Diagram 2] Capping and deprotection with reagents 1 and 2 are illustrated. A short peptide (WEGSKYA) was synthesized by standard Fmoc-based SPPS. After coupling of 5, some resin was removed from the vessel and treated with reagent 1 or reagent 2 (in DMF with stoichiometric amount of lutidine). To deprotect and cleave these peptides from the resin, a cleavage cocktail containing TFA, 5% anisole, 5% thioanisole and 5% water was used, since the use of triisopropylsilane is described as causing reduction of aldehydes to alcohols. After 2 h treatment with the cleavage cocktail, the peptides were precipitated with cold diisopropyl ether and analyzed by LCMS. This revealed that capping with both reagents occurred quantitatively, but reagent 2 was successfully deprotected to give the keto-capped peptide 5, whereas reagent 1 was still quantitatively protected as an acetal. The crude mixture was again redissolved in TFA and deprotection was finally observed after 24 h at room temperature. [Diagram 3] 1 illustrates the capping of a peptide sequence using a cap-capt reagent according to the present invention. [Figure 4] Two HPLC chromatograms are shown: Figure 4a shows the HPLC chromatogram of a mixture of WEGSKYA (SEQ ID NO: 1) 6 and keto-capped GSKYA (SEQ ID NO: 2) 5; Figure 4b shows the HPLC chromatogram after 2 hours of incubation with amino-oxy resin 3. [Diagram 5] Two HPLC chromatograms are shown. Figure 5a illustrates the HPLC chromatogram at 214 nm of the crude mixture of angiotensin I and the termination sequence after SPPS. Figure 5b illustrates the HPLC chromatogram at 214 nm of angiotensin I after incubation with amino-oxy resin 3. As a model system, biological 10mer angiotensin I (DRVYIHPFHL) (SEQ ID NO: 3) was synthesized. To stress conditions, a single coupling with only one equivalent of amino acid per step was performed. LCMS analysis of the crude material revealed a major termination after proline and additional terminations after valine and tyrosine. All of these were quantitatively capped with reagent 2 (M+84) (Figure 5a). The mixture was dissolved in acetate buffer at pH=4.5 and incubated on aminooxy resin 3 for 2 h to obtain full-length angiotensin I (Figure 5b) with good purity. Of note is the complete removal of the keto-capped truncated Cap-PFHL (SEQ ID NO: 4), which co-elutes with the major product. [Figure 6]Four HPLC chromatograms are shown. As a model peptide, 28mer des-octanoyl ghrelin (GSSFLSPEHQRVQQRKESKKPPAKLQPR) (SEQ ID NO: 5) was synthesized on a 20 μmol scale. After SPPS, crude des-octanoyl ghrelin was obtained with a purity of 72%. The crude product was dissolved in acetate buffer (pH=4.5, 0.1 M) and analyzed by HPLC-MS (Figure 6a). The crude product was divided into two equal aliquots. The first aliquot was purified by preparative HPLC (Figure 6b), and the second aliquot was incubated on amino-oxy resin 3 for 2 h (Figure 6c). HPLC purification gave a purity of 99% and a yield (for the initial resin loading, respectively) of 25%. The strategy using cap-capt reagent gave a purity of 92% and a yield of 48% (Figure 6c). Figure 6d illustrates the HPLC chromatogram when the product was subjected to preparative HPLC. [Figure 7] Schematic representation of the use of capping and trapping reagents for HPLC-free peptide purification. During acid cleavage and peptide deprotection, the acetal-containing capping moiety is converted to a ketone, which can be chemoselectively trapped by amino-oxy resin. The full-length peptide remains in solution as a pure product. EXAMPLES
[0062] Example 1 General procedure for ester hydrolysis (see also FIG. 1) (see Tartaggia, S.; Fogal, S.; Motterle, R.; Ferrari, C.; Pontini, M.; Aureli, R.; De Lucchi, O., Chemoenzymatic Synthesis of δ-Keto β-Hydroxy Esters as Useful Intermediates for Preparing Statins. European Journal of Organic Chemistry, 2016, Vol. 2016(19), pp. 3162-3165): To a solution of methyl 2,2-dimethoxyacetate, ethyl 2,2-diethoxyacetate, or fractone (75 mmol) in EtOH (100 mL), respectively, was added NaOH (2 M aqueous, 50 mL). The reaction was stirred at room temperature for 4 h, after which the EtOH was removed under reduced pressure. The aqueous phase was then washed with diisopropyl ether (2×20 mL), acidified with 2M HCl, and extracted with EtOAc (3×100 mL). 2 SO 4 After drying at 40° C. and removing the solvent under reduced pressure, the desired product was obtained as a slightly yellow oil (2,2-dimethoxyacetic acid (1a'); 2,2-diethoxyacetic acid (1a): 85%; 2a: 79%, respectively). That is, compound 1 was obtained in 85% yield and compound 2 in 79% yield. This means that no chromatographic purification was required, only extraction in the first step and filtration in the second step, to obtain the capping reagent in good yield and purity. Scaling up to 100 g of anhydride in a single synthetic run was easily possible. As the basis for the capture resin, a PEG-based polymer (AminoPEGA® resin) was used, which is suitable for working with both organic and aqueous solvents. Boc-amino-oxy-acetic acid was incorporated onto the resin (step c) and deprotected with TFA (step d) (see also FIG. 1).
[0063] The product was used in the next step without further purification.
[0064] General procedure for anhydride synthesis (see also Figure 1): CH of 2,2-dimethoxyacetic acid (1a'), 2,2-diethoxyacetic acid (1a) or 2-(2-methyl-1,3-dioxolan-2-yl)acetic acid (2a) (20 mmol). 2 Cl 2 To the medium solution was slowly added N,N'-dicyclohexylcarbodiimide (10 mmol) at 0°C. The reaction was allowed to warm to room temperature under vigorous stirring. After 3 h, the reaction was filtered to remove solids, and the filtrate's solvent was removed under reduced pressure to give the two anhydrides, each in quantitative yield, as slightly yellow resins, which were used without further purification.
[0065] 2,2-Dimethoxyacetic anhydride (1'): 1 H NMR (400 MHz, chloroform-d) δ ppm 3.45 (s, 12 H) 4.93 (s, 2 H) 2,2-Diethoxyacetic anhydride (1): 1 H NMR (400 MHz, chloroform-d) δ ppm 1.10 (t, 12 H) 3.50 (q, 8 H) 4.93 (s, 2 H) 2-(2-methyl-1,3-dioxolan-2-yl)acetic anhydride (2): 1 H NMR (400 MHz, chloroform-d) δ ppm 1.50 (s, 6 H) 2.82 (s, 4 H) 3.98 (s, 8 H)
[0066] Synthesis of amino-oxy PEGA resin (3) (see also Figure 1): Amino-PEGA-resin (Novabiochem, 1.00 g, loading 0.37 mmol / g) was washed with DMF (5 x 10 mL). Boc-amino-oxy-acetic acid (212 mg, 1.11 mmol), HATU (380 mg, 1.00 mmol) and DIPEA (383 μL, 2.2 mmol) were mixed in DMF (10 mL) and added to the resin. After 30 min shaking at room temperature, the resin was washed with DMF and Kaiser test confirmed the absence of residual amino groups. TFA + 2% H 2The resin was treated with O for 1 h and then washed with acetate buffer (0.1 M, pH = 4.5) to yield the desired aminooxy resin.
[0067] Example 2 Peptide synthesis: Automated Fmoc-based solid-phase peptide synthesis was performed using a Syro I synthesizer and Rink-AmideTentagel resin (loading 0.19 mmol / g). Fmoc deprotection was performed by treating the resin with 20% piperidine in DMF for 2x5 min. Successive Fmoc-protected amino acids (0.25 M in NMP + 0.25 M HOAt) were coupled on the resin using HCTU (0.8 M) and N-methylmorpholine (NMM, 3 M in DMF) for 15 min at room temperature. If not otherwise stated, for each coupling, 5 equivalents of amino acid (respectively relative to the resin loading) were used and the coupling was repeated twice. Capping of free residual amino functions was performed by treating the resin with 2-(2-methyl-1,3-dioxolan-2-yl)acetic anhydride (2) and lutidine (both 0.5 M in DMF; 20 equivalents, respectively relative to the resin loading). TFA / Thioanisole / Anisole / H 2 Cleavage from the resin was carried out using HO (85:5:5:5). The resin was incubated with this cocktail for 30 min, and then the cleavage solution was kept at room temperature for 1-2 h. After reducing the volume of the solution under a stream of nitrogen, the crude peptide was obtained by precipitation with diisopropyl ether and centrifugation.
[0068] Example 3 Peptide sequence H-SKSYS-resin (SEQ ID NO:6) (10 μmol) was synthesized according to the standard method described above, except for capping, acetic anhydride was used instead of 2. The resin was divided into two equal portions (5 μmol each). The first aliquot was treated with a solution of 2 (0.5 M in DMF, 0.5 mL) and NMM (N-methylmorpholine) (3 M in DMF, 100 μL) for 15 min. The second aliquot (aliquot 2) was treated with a solution of 2a (0.5 M in DMF, 0.5 mL), NMM (3 M in DMF, 100 μL) and HCTU (2-(6-chloro-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium-hexafluorophosphat) (0.8 M in DMF, 250 μL) for 15 min. TFA / thioanisole / anisole / H 2 Cleavage from the resin was carried out using 5-methyl-2,4-dihydro-1,2,5-trimethylphenylacetamide (85:5:5:5). Both capping methods showed complete capping of the terminal amino groups (Figure 3). MS(ESI):654.28[M+H] +
[0069] Example 4 Peptide sequence H-GSKYA-resin (SEQ ID NO: 7) (15 μmol) was synthesized following the standard method described above, except for using acetic anhydride instead of 2 for capping. The resin was split into three equal portions (5 μmol each) as illustrated in FIG. 2. The first aliquot (aliquot 1) was treated with a solution of 1 (50 μmol) and 2,6-lutidine (50 μmol) in DMF (1 mL) for 15 min. The second aliquot (aliquot 2) was treated with a solution of 2 (50 μmol) and 2,6-lutidine (50 μmol) in DMF (1 mL) for 15 min. TFA / thioanisole / anisole / H 2Cleavage from the resin was carried out using 0 (85:5:5:5). Both aliquots 1 and 2 showed complete capping of the terminal amino groups. The acetal of aliquot 2 was completely deprotected to yield the corresponding ketone, while the acetal protection of aliquot 1 remained intact after the cleavage procedure. The remaining aliquot (aliquot 3) was subjected to two further solid phase synthesis steps to generate the peptide H-WEGSKYA after cleavage from the resin.
[0070] Example 5 Keto-capped GSKYA (SEQ ID NO:2) (5) (1 μmol) and H-WEGSKYA (SEQ ID NO:1) (6) (1 μmol) were dissolved in acetate buffer (0.1 M, pH = 4.5) and analyzed by HPLC-MS (Figure 4a). Amino-oxy PEGA resin (3) was added to the mixture, and after 2 h, the supernatant was analyzed by HPLC-MS, showing that only 6 remained in solution (Figure 4b).
[0071] Example 6 Angiotensin I was synthesized following the procedure described above, varying the amount of amino acid used for coupling: instead of 2 × 5 equivalents of Fmoc-amino acid, a single coupling with 1 equivalent of amino acid was performed. The crude product was dissolved in acetate buffer (0.1 M, pH = 4.5) and analyzed by HPLC-MS (Figure 5a). Amino-oxy PEGA resin (3) was added to the mixture, and after 2 h, the supernatant was analyzed by HPLC-MS, showing that most of the impurities were successfully removed (Figure 5b).
[0072] Example 7 Following the general peptide synthesis procedure described above, Des-octanoyl ghrelin (GSSFLSPEHQRVQQRKESKKPPAKLQPR) (SEQ ID NO: 5) (20 μmol) was synthesized. The crude product was dissolved in acetate buffer (0.1 M, pH = 4.5) and analyzed by HPLC-MS (Figure 6a), which resulted in containing 72% of the desired product. The mixture was divided into two aliquots. The first aliquot was purified by preparative HPLC to produce the desired product with 99% purity and 25% yield (Figure 6b). The second aliquot was incubated with amino-oxy PEGA resin (3) for 2 h. The desired product was isolated with 92% purity and 48% yield (Figure 6c). By subjecting this product to preparative HPLC chromatography, the product could be isolated with a final purity of 99% and an overall yield of 30% (Figure 6d). [Table 1]
Claims
1. 1. Use of a capping and capturing (cap-capt) reagent comprising a capping moiety and a capturing moiety in solid phase peptide synthesis, comprising: the capping moiety is a carboxylic acid or an activated carboxylic acid and the capture moiety is a protected carbonyl group; The capping and capture reagent comprises: [Case 1] The use of a capping and capture reagent selected from:
2. A method for solid phase peptide synthesis (SPPS) in which individual amino acids are coupled to each other via Fmoc-chemistry, wherein after at least one coupling step, a capping and capture reagent is used to cap the defective peptide sequences, the capping and capture reagent comprising: [Case 2] The method is selected from the group consisting of
3. 3. The method of claim 2, wherein the capping moiety of the capping and capture reagent is a carboxylic acid, further comprising the step of activating the capping moiety with an activating agent, thereby preparing an activated carboxylic acid, the activating agent corresponding to an activating agent of the Fmoc-chemistry reaction.
4. A method for the purification of a full-length synthetic peptide, comprising: - carrying out the method for solid phase peptide synthesis according to claim 2 or 3, - cleaving the peptide synthesized in the previous step from the solid phase, - deprotecting the capture moiety, and - binding the deprotected capture moiety to a solid resin support, thereby binding at least one failure peptide to the solid resin support; and - separating the full-length synthetic peptide from the solid resin support containing said failure peptides; A method comprising:
5. 5. The method of claim 4, wherein the solid resin support is an aminooxy resin or a hydrazine resin.
6. 6. The method of claim 4 or 5, wherein separation of the full-length synthetic peptide from the solid resin support containing the mismatched peptides is performed by centrifugation or filtration.
7. 1. A kit comprising at least one capping and capture reagent and at least one aminooxy resin, or hydrazine resin, wherein the capping and capture reagent is [C3] The kit is selected from the group consisting of:
8. Use of the kit according to claim 7 for the purification of a peptide synthesised on a solid support.
Citation Information
Patent Citations
Reagents that facilitate the purification of compounds synthesized on a solid support
WO2003017930A2
